Johnson & Johnson CFO Joe Wolk expects the company to surpass its long-term growth target of 5% to 7%. Wolk projected double-digit enterprise growth by the end of the decade during the Deutsche Bank Healthcare Summit on September 17, 2026. The company will present formal updated expectations at its investor day in December.
This forecast arrives as J&J faces a significant patent cliff in 2026. The company anticipates $4 billion to $4.5 billion in revenue exposure from loss of exclusivity. Major drugs impacted by these patent expirations include XARELTO and STELARA.
Wolk expects marketed products and a robust late-stage pipeline to offset these revenue impacts. He identified the newly approved OTTAVA surgical robotics platform as a significant long-term driver. Management does not expect the platform to contribute material revenue in the near future.